Midterm results of uterine artery embolization using narrow-size calibrated embozene microspheres
Purpose: To evaluate safety and efficacy of uterine artery embolization using narrow-size-range polyphosphazene-coated hydrogel microspheres (Embozene, CeloNova Biosciences, Newnan, GA). Methods: Between May 2006 and September 2008, a total of 121 consecutive patients (mean ± SD age 42.1 ± 5.4 years...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2011
|
| In: |
CardioVascular and interventional radiology
Year: 2011, Jahrgang: 34, Heft: 2, Pages: 295-305 |
| ISSN: | 1432-086X |
| DOI: | 10.1007/s00270-010-9986-8 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00270-010-9986-8
|
| Verfasserangaben: | Ulrike Stampfl, Boris Radeleff, Christof Sommer, Sibylle Stampfl, Angelika Dahlke, Nadine Bellemann, Hans-Ulrich Kauczor, Goetz M. Richter |
| Zusammenfassung: | Purpose: To evaluate safety and efficacy of uterine artery embolization using narrow-size-range polyphosphazene-coated hydrogel microspheres (Embozene, CeloNova Biosciences, Newnan, GA). Methods: Between May 2006 and September 2008, a total of 121 consecutive patients (mean ± SD age 42.1 ± 5.4 years, range 30.5–51.5 years) were enrolled onto this single-center study. The primary study endpoint was safety as assessed by the society of interventional radiology (SIR) classification. The secondary endpoint was efficacy, which was based on a 1-year magnetic resonance imaging study and relief of symptoms documented by the Medical Outcomes Study 36-Item Short-Form Health Survey questionnaire over a 2-year interval. Results: The mean ± SD diameter of the dominant fibroid was 6.4 ± 2.6 (range, 2.9–13.9) cm and the mean volume 137.2 ± 245.1 (range, 5.3–1184) ml. Most patients had multiple fibroids with 11% more than 10. A total of 240 of 242 interventions were completed as planned, a technical success rate of 99.2%. According to the SIR classification, one type A, eight type C, and one type D complication occurred. Total devascularization was noted in 96% (116 of 121) of dominant fibroids. Volume decrease was 4% at 2 weeks, 52% (P < 0.001) at 3 months, 78% (P < 0.001) at 6 months, and 91% at 12 months (P < 0.001). The latter difference was statistically significant (P = 0.007). A total of 92% had improved hypermenorrhea at 1 year and 94% at 2 years. Dysmenorrhea was improved in 96% at 1 year and in 95% at 2 years. The overall health status score was 60.4 ± 26.2 points at baseline and 96.9 ± 3.8 after 1 year (P = 0.0019). Conclusion: Uterine artery embolization with Embozene microspheres is a safe procedure. Its efficacy is demonstrated by high fibroid devascularization and volume reduction rates and significant improvements of clinical symptoms and quality-of-life scores during follow-up. |
|---|---|
| Beschreibung: | Online veröffentlicht: 15 October 2010 Gesehen am 20.10.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1432-086X |
| DOI: | 10.1007/s00270-010-9986-8 |